Inomagen Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 4

Inomagen Therapeutics General Information

Description

Developer of a non-viral gene therapy designed to treat the underlying mechanisms of atrial fibrillation. The company offers a proprietary gene delivery system utilising reversible electroporation for targeted, minimally invasive transvenous administration of genetic material to the cardiac atrium, enabling patients to get treatment with various stages of atrial fibrillation by addressing molecular causes and reducing arrhythmia and fibrosis, enabling an alternative to existing therapies that do not target disease origins.

Contact Information

Formerly Known As
Rhythm Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 400 North Aberdeen Street
  • Suite 900
  • Chicago, IL 60642
  • United States
+1 (312)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 400 North Aberdeen Street
  • Suite 900
  • Chicago, IL 60642
  • United States
+1 (312)

Inomagen Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inomagen Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 03-Sep-2026 Completed Pre-Clinical Trials
9. Later Stage VC 19-Jun-2025 Completed Pre-Clinical Trials
8. Later Stage VC 12-Apr-2024 Completed Pre-Clinical Trials
7. Later Stage VC 01-Sep-2022 Completed Pre-Clinical Trials
6. Grant 11-Mar-2022 Completed Pre-Clinical Trials
5. Grant 01-May-2021 Completed Pre-Clinical Trials
4. Grant 14-Apr-2021 Completed Pre-Clinical Trials
3. Accelerator/Incubator 15-Dec-2015 Completed Startup
2. Angel (individual) 21-Nov-2014 $200K $200K Completed Startup
1. University Spin-Out 01-Jan-2014 Completed Startup
To view Inomagen Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Inomagen Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inomagen Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Portal Innovations Venture Capital Minority
NIH Seed Not-For-Profit Venture Capital
National Heart, Lung, and Blood Institute Government
National Institutes of Health Government
To view Inomagen Therapeutics’s complete investors history, request access »

Inomagen Therapeutics FAQs

  • When was Inomagen Therapeutics founded?

    Inomagen Therapeutics was founded in 2014.

  • Where is Inomagen Therapeutics headquartered?

    Inomagen Therapeutics is headquartered in Chicago, IL.

  • What is the size of Inomagen Therapeutics?

    Inomagen Therapeutics has 6 total employees.

  • What industry is Inomagen Therapeutics in?

    Inomagen Therapeutics’s primary industry is Drug Discovery.

  • Is Inomagen Therapeutics a private or public company?

    Inomagen Therapeutics is a Private company.

  • What is Inomagen Therapeutics’s current revenue?

    The current revenue for Inomagen Therapeutics is .

  • How much funding has Inomagen Therapeutics raised over time?

    Inomagen Therapeutics has raised $540K.

  • Who are Inomagen Therapeutics’s investors?

    Portal Innovations, NIH Seed, National Heart, Lung, and Blood Institute, and National Institutes of Health have invested in Inomagen Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process